A new molecular target therapy for gastric can cer targeting nuclear translocation of the CTF of EGFR ligands

HB-EGF-CTF核易位增加胃癌细胞的运动和侵袭。人胃癌pT3/4期肿瘤中HB-EGF-CTF的核免疫反应性明显高于pT1/2期肿瘤。这些结果表明HB-EGF-CTF核易位诱导胃癌侵袭（Shimura T等）。BMC癌症2012，已出版)。AR核易位在体外和体内显著诱导化疗耐药，AR核染色被认为是人胃癌预后不良的重要因素。由于这些结果，AR核易位降低了对抗癌药物的化学敏感性，可能与人类胃癌预后不良有关（Yoshida M, Shimura T, et al.）。癌症科学2012)。

HB-EGF-CTF nuclear translocation increased motility and invasion of gastric cancer cell. The nuclear immunoreactivity of HB-EGF-CTF was significantly increased in stage pT3/4 tumors compared with pT1/2 tumors in human gastric cancer. These results suggested that HB-EGF-CTF nuclear translocation induce gastric cancer invasion(Shimura T, et al. BMC Cancer 2012, in press).AR nuclear translocation significantly induced chemoresistance in vitro and in vivo, and AR-nuclear staining was extracted as a significant poor prognostic factor in human gastric cancer. As these results, AR nuclear translocation reduces chemosensitivity to anti-cancer drugs and would be associated with poor prognosis in human gastric cancer(Yoshida M, Shimura T, et al. Cancer Sci 2012).